
Wednesday, April 16, 2025 6:39:23 AM
He has the most to gain with ELTP's success as the largest shareholder.
Yes, and he also is the only one to gain with Mikah's success. He has repeatedly used Mikah to drain wealth from Elite shareholders, and now he is set up to make himself a Big Beautiful Deal for Mikah that leaves Elite shareholders out in the cold. Mikah has never been anything other than a parasite that sucks wealth from Elite, and it will continue to do so until we make it stop. Our biggest Mikah expense ever will be at the time of buyout. Hakim will make a secret side deal for Mikah that will have a detrimental impact on the buyout price for Elite, and we will never know how badly we were screwed or how massively Mikah wins again.
Ask yourself: as the largest shareholder in Elite, wouldn't it be to Hakim's benefit to clear the 79 million warrants that drag down our net income every time the share price goes up? Why wouldn't he execute these cashless warrants now so they stop being a liability for the rest of us? How did awarding himself 79 million warrants benefit the rest of Elite shareholders? How does their continued existence help anyone but Hakim?
No other CEO in America acts like this. His self-serving behavior is foreign. Hakim's repeated failures at fulfilling his fiduciary duty has been a disaster for Elite shareholders and will become a catastrophe at buyout. Just because he is the largest shareholder in Elite doesn't mean that his interests are aligned with the rest of Elite shareholders. The parasite Mikah is getting fatter by the minute and will be fully engorged after the buyout. Flick the tick. Tell Hakim if he is serious about pursuing a buyout now then it is time to get rid of Mikah forever and get rid of his warrants, too. Repeal the Mikah Tax.
.
Repeal the Mikah Tax -- To be paid by all shareholders at buyout
1. Cost of Second Tier Suitors
2. Cost of Secret Side Deal with Hakim
3. Cost of Mikah litigation
4. Cost of remaining OTC
Recent ELTP News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/23/2025 11:05:31 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/16/2025 11:05:36 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2025 08:40:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2025 12:10:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2025 09:56:40 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2025 09:05:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2024 09:20:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/02/2024 09:35:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/18/2024 09:35:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2024 09:51:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 09:30:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/28/2024 09:23:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/23/2024 12:27:32 PM
- ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition • InvestorsHub NewsWire • 10/23/2024 12:03:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2024 08:47:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/27/2024 08:30:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 09:16:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:05:53 PM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM